Advanced Search

Study Preview



Study Title and Description

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea.



Key Questions Addressed
8 Key Question 8 - Case studies/series and potential harms of nonstandard interventions for CDI
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea.
Author McPherson S., Rees CJ., Ellis R., Soo S., Panter SJ.
Country Department of Gastroenterology, South Tyneside District Hospital, Harton Lane, South Shields, NE34 0PL, United Kingdom.
Year 2006
Numbers Pubmed ID: 16525744
1444 (internal)

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Question 4 - Case studies/series and potential harms of nonstandard interventions for CDI (Table C11)
Design Details
Question... Follow Up Answer Follow-up Answer
Study Focus Treatment for recurrent or refractory C. difficile infection
  • Comments Comments (
    0
    ) |
Subject/Study Details 14 patients with diarrhea and C. difficile toxin positive stools despite standard antibiotics Age = 79 (54-91) years (median [range])
  • Comments Comments (
    0
    ) |
Interventions Intravenous intramuscularmunoglobulin (intravenous intramuscularmunoglobulin (IVIG)) 150-400 mg/kg x 1-2 doses
  • Comments Comments (
    0
    ) |
Clinical Diarrhea Outcomes 9 /14 (64%) resolved diarrhea 3/9 surviving had a recurrence
  • Comments Comments (
    0
    ) |
C. difficile Toxin, C. difficile Culture, or Other
  • Comments Comments (
    0
    ) |
Adverse Effects (AE) Harms Reported as none
  • Comments Comments (
    0
    ) |




Results & Comparisons

No Results found.